Forte Biosciences Prices $150 Million Public Offering

Forte Biosciences ( (FBRX) ) has issued an announcement.

On April 8, 2026, Forte Biosciences, Inc. priced a public offering of 5,709,936 shares of common stock at $26.27 per share, with gross proceeds expected to be about $150 million and closing anticipated around April 10, 2026, subject to customary conditions. The underwriters also received a 30-day option to purchase up to an additional 856,490 shares, and the deal is being led by Guggenheim Securities and Barclays under an effective SEC shelf registration.

Forte expects to receive approximately $141 million in net proceeds, or up to about $162 million if the underwriters’ option is fully exercised, and plans to use the capital for working capital, general corporate purposes, and funding clinical development of FB102 and other research. As part of the offering, argenx BV has taken a strategic stake in Forte, underscoring external confidence in its autoimmune pipeline and potentially strengthening its strategic positioning in the competitive immunology space.

The most recent analyst rating on (FBRX) stock is a Sell with a $24.50 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.

Spark’s Take on FBRX Stock

According to Spark, TipRanks’ AI Analyst, FBRX is a Neutral.

The score is held down primarily by weak financial performance driven by no revenue, widening losses, and accelerating cash burn. Technicals are mixed with soft near-term trend indicators, while valuation provides limited support due to negative earnings and no dividend data.

To see Spark’s full report on FBRX stock, click here.

More about Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, advancing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad indications. Based in Dallas and listed on Nasdaq as FBRX, the company targets immune-mediated conditions through novel biologic drug development.

Its strategy centers on progressing FB102 through clinical trials and supporting related research activities aimed at addressing unmet needs in autoimmune care. Forte’s market focus positions it within the competitive immunology and biologics segment, where clinical differentiation and sustained access to capital are critical for advancing pipeline assets and maintaining long-term growth prospects.

Average Trading Volume: 226,875

Technical Sentiment Signal: Buy

Current Market Cap: $364.8M

For a thorough assessment of FBRX stock, go to TipRanks’ Stock Analysis page.